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1Liver biochemistry is not only a common screening test in the outpatient and primary care settings, but also increas-
ingly assessed as part of insurance medicals.1 Bilirubin has 
been shown to be an effective antioxidant both in vitro2 and in 
vivo,3 positively related to the total serum antioxidant capac-
ity in humans4 and suppress the oxidation of LDL choles-
terol.5 Several population studies have reported a significant 
negative correlation between serum bilirubin concentrations 
and blood pressure (BP),6 severity of atherosclerosis,7 inci-
dent coronary heart disease,8 and with decreased mortality 
risk.9,10 Interestingly, there is also evidence for both positive 
and negative relationships with mortality for alanine trans-
aminase (ALT),11–15 even though higher, not low, ALT is also 
considered a marker for nonalcoholic fatty liver disease.16 In 
contrast, γ-glutamyltranspeptidase (GGT) is associated with 
a positive relationship to mortality and cardiovascular dis-
ease.11,15,17–19 A potential causal role for bilirubin is supported 
by studies of human sequence variations in the UGT1A1 gene, 
which result in moderate increases in plasma bilirubin and a 
decreased risk for the development of cardiovascular disease 
(CVD).6 Furthermore, in animal studies, moderate hyperbili-
rubinemia, induced either by knockout of UGT1A1 or block-
ade with indinavir, was associated with a 50% decline in BP 
response to angiotensin II and no effect on glomerular filtra-
tion rate.20,21 Several studies in both genetic and experimental 
models have demonstrated that heme oxygenase-1 induction 
(which can increase bilirubin levels) can attenuate the devel-
opment of hypertension, as well as lower BP, in established 
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hypertension.22,23 To date, most large studies have analyzed sin-
gle liver tests, and there is no data on predictive value of these 
markers for cardiovascular outcomes or the combined effects 
of different liver tests on outcomes. It is unclear whether the 
effects of bilirubin and liver enzymes have an impact on hyper-
tensive patients in terms of long-term survival or BP control. 
In this study, we propose to test whether serum bilirubin and 
liver enzyme levels within the normal range have independent 
effects on mortality and BP control and whether any of these 
tests alone or in combination have incremental predictive value 
for cardiovascular mortality in treated hypertensive patients.
Methods
Study Setting and Study Population
The Glasgow BP clinic provides a secondary and tertiary level service 
to individuals with hypertension from the West of Scotland. Details 
of the cohort and clinical measurements and outcome assessment 
are presented in Methods in the online-only Data Supplement and 
described previously.24
Statistical Analysis
All analyses were restricted to individuals in the database with liver 
tests measured for at least one variable (N=12 000) at the registration 
visit (Figure S1 in the online-only Data Supplement). Analyses were 
performed in the overall population and in the subset after exclud-
ing individuals with high liver test values (values above 4 standard 
deviations, which are indicative liver injury or disease)—defined as 
aspartate transaminase (AST) >100 IU/L (n=198, 1.8%), ALT>100 
IU/L (n=408, 4.0%), GGT>100 IU/L (n=762, 7.2%), alkaline phos-
phatase (ALP) >240 IU/L (n=1041, 9.1%), and total bilirubin >30 
μmol/L (n=145, 1.3%). The distributions of liver enzymes were 
reviewed, and all except albumin showed non-normal distributions 
and were logarithmically transformed for analysis. Pearson correla-
tions between liver enzymes and bilirubin were calculated. Multiple 
Imputation using Chained Equation was used for imputing missing 
values of liver test variables (GGT=1546, AST=941, ALT=2168, 
ALP=638, and total bilirubin =1110) and cholesterol (n=1012). The 
diagnostics of 10 imputed data sets for each variable were performed 
and the convergence was tested.
The characteristics of the study population in men and women were 
compared using independent t tests and analysis of variance, where 
appropriate, for continuous variables and Chi-Square tests for categor-
ical variables. The study population was divided into groups based on 
quartiles of serum liver enzymes. Cox proportional hazard (Cox-PH) 
models were used to analyze the influence of baseline liver enzymes 
on all-cause, CVD, ischemic heart disease, stroke, and non-CVD mor-
tality. The covariates included were sex, baseline age, body mass in-
dex, smoking status (never versus ever), systolic BP (SBP), diastolic 
BP (DBP), total cholesterol, diabetes mellitus status, alcohol use, 
estimated glomerular filtration rate, and final achieved SBP. A vari-
able on year of first visit strata (epochs) was used to adjust the secular 
trend in mortality and was divided into 5 categories (first visit 1977 
or before, between years 1978 and 1985, 1986 and 1993, 1994 and 
2001, and 2002 and thereafter). The proportional hazards assumption 
was assessed through examination of log-minus-log plots.25 Initially, 
bilirubin and other concomitant liver function tests were assessed as 
categorical variables in quartiles (Models 1–5) adjusted for each other 
and the above described covariates. Hazard ratios (HR) were also gen-
erated per one standard deviation increase in liver tests and with all 
other covariates as in the above models. These analyses were repeated 
after imputing missing data for liver tests and cholesterol. Given the 
potential nonlinear relationship of the liver function variables and 
time to mortality, a regression spline model was also set up to further 
smoothen the hazard functions. The relative log hazard functions with 
associated 95% confidence intervals (CIs) were plotted in a graph.
Regression modeling with generalized estimating equations was 
used to study the association of liver biochemistry variables with 
follow-up BP.26 Individuals with at least 4 annual BP assessments in 
the first 5 years of follow-up and survival up to a minimum of 5 years 
period were included in this analysis. The association was adjusted 
for baseline age, sex, alcohol and tobacco use, and estimated glo-
merular filtration rate. The models were repeated after stratifying the 
population based on different baseline variables, such as age, body 
mass index, and alcohol use.
The Cox PH models were fitted to data from all participants and 
then predictive ability was assessed using measures of risk discrimi-
nation and reclassification by fitting models with and without serum 
bilirubin. Harrel’s c-index, net reclassification improvement (NRI), 
and Integrated Discrimination Improvement were used to assess dis-
crimination and reclassification (see Methods in the online-only Data 
Supplement). We computed time-to-event survival–based NRI and 
category-free reclassification measures (cNRI). The cNRI requires 
that the subject’s risk probability changes, without any limit, to de-
fine an upward or downward reclassification, whereas for NRI, we 
used risk cut-offs of 0% to 10%, 10% to 20%, and >20%. Integrated 
Discrimination Improvement is independent of category and consid-
ers separately the actual change in calculated risk for each individual 
for those with and those without events (ie, not merely the direction 
of change as with the cNRI). Reclassification over different periods of 
follow-up—10 years, 20 years, and 35 years—were generated. Stata 
Version 12.0 (Statacorp) was used for all statistical analysis. The R 
packages nricens and PredictABEL were used for risk discrimination 
and reclassification analyses.
Results
Demographic and Clinical Characteristics of the 
Study Population
The study population was middle-aged (50.8+14.6), 53% 
female, overweight (body mass index =27.6+5.8), and hyper-
tensive (SBP=163.9+29.2 and DBP=97.2+19.8). Forty-four 
percent were smokers and nearly two thirds (60%) drank >6 
U of alcohol per week. The BP after 5 years of follow-up 
(SBP=147.9+22.5 and DBP=87.9+11.9) was significantly 
lower than the baseline BP. Less than one fifth of the study 
population first presented to clinic before 1980 (17%) and 
22% first presented after 2003. The proportions of Gilbert 
syndrome (serum bilirubin >17 μmol/L) in men and women 
were 7.1% and 5.7%, respectively. There were moderate 
bivariate correlations between AST, ALT, and GGT, but bili-
rubin and ALP showed little correlations to each other and 
other enzymes (Figure S2). The full demographic and clinical 
characteristics are given in Table. Table S1A–S1E provides 
demographic and clinical characteristics stratified by quar-
tiles of liver enzymes and bilirubin.
Longitudinal Changes in Blood Pressure and Liver 
Biochemistry
3920 subjects who had at least 3 annual BP recordings in the 
first 5 years were included in the generalized estimating equa-
tions analyses. The median (interquartile range) of the number 
of annual BP measurements per individual was 5 (4–6). After 
adjustment for conventional covariates, including ALT, GGT, 
ALP, and bilirubin, the annual rate of change in BP in the first 
5 years of follow-up was −3.1/−1.61 mm Hg (95% CI −3.2 to 
−2.9/−1.68 to −1.55 mm Hg), and this is considered the treat-
ment effect on BP. The specific effect of ALT and bilirubin 
on longitudinal BP change was opposite to that of ALP and 
GGT (Table S2). One SD increase in ALT and bilirubin was 
associated with a 0.4 mm Hg decrease in SBP over 5 years 
after accounting for the annual reduction in BP because of 
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treatment effects and the effect of other covariates (Figure S3). 
In contrast, each SD increase in ALP or GGT was associated, 
respectively, with a 2.1 or 0.9 mm Hg rise in SBP over 5 years. 
The BP effects of bilirubin and ALT were clearly apparent in 
subgroups who were >55 years old or body mass index >25 
or consumed >6 U/week of alcohol, whereas the BP effect of 
ALP and GGT were consistent in all subgroups. An effect on 
DBP was observed only for ALP and GGT.
Survival Analysis and Risk Prediction
The total time at risk was 173 806 person years (p-y) with 
median survival time of 32.2 years from initial clinic appoint-
ment. The incidence rates were 17.59 (95% CI, 16.98–18.22), 
10.08 (95% CI, 9.62–10.56), 5.40 (95% CI, 5.07–5.76), 2.50 
(95% CI, 2.27–2.74), and 7.51 (95% CI, 7.11–7.93) per 1000 
p-y of follow-up for all-cause, CVD, ischemic heart disease, 
stroke, and non-CVD mortality outcomes, respectively.
In the multivariable Cox-PH model, each SD increase in ALT 
and bilirubin were associated with 14% (HR=0.86; 95% CI, 
0.81–0.95) and 11% (HR=0.89; 95% CI, 0.85–0.94) decrease in 
all-cause mortality, respectively. Similarly, each SD increase in 
GGT and ALP were associated with 11% (HR=1.11; 95% CI, 
1.04–1.18) and 25% (HR=1.25; 95% CI, 1.18–1.33) increase 
in all-cause mortality, respectively. The imputation of missing 
variables did not affect the results (Figure S4). Bilirubin and 
ALT quartiles in the multivariable adjusted Cox-PH model 
showed a clear negative relationship with all-cause, CVD, and 
non-CVD mortality (Table S3). The cubic spline regression 
plots for all-cause mortality are presented in Figure.
The sequential addition of different liver biochemistry 
measurements singly or in combination produced trivial or 
no change in the C statistic (Table S5). The addition of a 
single liver biochemistry to the risk models showed bilirubin 
improved cNRI by 16.5% and 17.5%, respectively, for 35 
year and 20 year CV mortality, but not for 10 year mortality. 
Inclusion of bilirubin and ALP resulted in a 29.9%, 30.4%, 
and 21.9% improvement in cNRI for 35 year, 20 year, and 10 
year CV mortality, respectively, and this was similar when 
all the liver biochemistry tests were included in the model. 
The corresponding Integrated Discrimination Improvements 
were 1.5%, 1.1%, and 0.88% for 35 year, 20 year, and 10 
year CV mortality, respectively. Full risk discrimination and 
reclassification analyses are presented in Table S6.
Discussion
In the largest single cohort study of all liver biochemistry 
parameters (AST, ALT, GGT, ALP, bilirubin, and albumin) 
within the normal range, we show in treated hypertensive 
patients that the tests comprising the standard liver biochemis-
try panel have characteristic-independent effects on mortality, 
follow-up BP and a modest improvement in cardiovascular 
mortality prediction. Our findings are complementary to a 
recent large meta-analysis of liver enzymes mainly in the gen-
eral population (GGT, ALP, ALT, and AST) from Kunutsor et 
al,15 who showed a log-linear relationship between GGT and 
ALP with CVD risk and variable association between ALT 
and CVD end points. We show a negative association with 
Table.  Baseline Characteristics of the Study Population
Variables Total (N=12 000) Men (N=5680) Women (N=6320) P Value
Age, y, mean (SD) 50.88 (14.51) 49.87 (13.28) 51.79 (15.48) <0.001
BMI, kg/m2, mean (SD) 27.79 (5.82) 27.86 (5.26) 27.73 (6.27) 0.23
Smoking, n (%) 5254 (44.63) 2719 (48.89) 2535 (40.81) <0.001
Alcohol >6, n (%) 6676 (58.62) 3967 (73.56) 2709 (45.19) <0.001
SBP, mm Hg, mean (SD) 163.53 (28.45) 161.78 (26.69) 165.10 (29.86) <0.001
DBP, mm Hg, mean (SD) 96.91 (17.89) 98.00 (14.62) 95.93 (20.33) <0.001
TC, mmol/L, mean (SD) 5.94 (1.47) 5.83 (1.58) 6.03 (1.35) <0.001
eGFR, median (IQR) 73 (61–85) 76 (65–87) 70.0 (58–82) <0.001
Epochs
  ≤1980 2070 (17.25) 1024 (18.03) 1046 (16.55)
  1981–1993 4071 (33.92) 1959 (34.49) 2112 (33.42)
  1994–2002 3254 (27.12) 1479 (26.04) 1775 (28.09)
  ≥2003 2605 (21.71) 1218 (21.44) 1387 (21.95) 0.02
ALP U/L, median (IQR) 124.9 (78.1–183.0) 125.1 (78.1–181.0) 125.0 (78.1–185.0) 0.91
ALT U/L, median (IQR) 24.2 (17.0–34.0) 29.1 (21.0–41.0) 20.3 (15.0–28.0) <0.001
AST U/L, median (IQR) 23.1 (18.0–28.0) 24.9 (20.0–31.0) 21.3 (17.0–26.0) <0.001
GGT U/L, median (IQR) 27.4 (17.0–45.0) 34.1 (22.0–57.0) 21.4 (15.0–34.0) <0.001
Bilirubin μmol/l, median (IQR) 9.9 (7.0–13.0) 10.9 (8.0–14.0) 9.1 (7.0–12.0) <0.001
Albumin, g/L, mean (SD) 43.82 (3.79) 44.35 (3.87) 43.34 (3.65) <0.001
Last SBP, mm Hg, mean (SD) 147.97 (22.46) 146.67 (21.30) 149.14 (23.39) <0.001
Last DBP, mm Hg, mean (SD) 87.93 (11.85) 88.78 (11.77) 87.17 (11.88) <0.001
ALP indicates alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; GGT, γ-glutamyl transpeptidase; IQR, interquartile range;SBP, systolic blood pressure; SD, 
standard deviation; and TC, total cholesterol.
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mortality and longitudinal BP for serum bilirubin and ALT, 
but a positive association for GGT and ALP. Indeed higher 
baseline ALP and GGT showed a consistent relationship with 
higher follow-up SBP. Serum bilirubin and other liver func-
tion markers offered modest predictive utility (primarily for 
continuous NRI) over standard clinical risk factors in hyper-
tensive patients.
Bilirubin and ALT show similar associations with mortality 
and longitudinal BP, but the mechanisms are likely to be dif-
ferent. Bilirubin levels are strongly determined by genetic and 
environmental influences.6,27 The protective effect of bilirubin 
is supported by data that UGT1A1 genetic variants underly-
ing Gilbert’s syndrome are also protective against CVD.8 The 
antioxidant and anti-inflammatory properties of bilirubin may 
Figure. Regression spline Cox proportional hazard model for liver biochemistry parameters and all-cause mortality. The histogram 
describes the distribution of liver parameters. The hazard ratios are given in the secondary Y axis. The thick bold line represents the point 
estimate (hazard ratio) for the variables on X axis (liver parameters) and the light grey lines represent the 95% confidence intervals.
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partially explain the biological mechanisms associated with 
this negative relationship.5
In our study, higher bilirubin is associated with a lower 
baseline BP and greater longitudinal reduction in BP, which 
suggest that the protective effect of bilirubin can be partly 
explained by BP effects. For example, each μmol/L increase 
in serum bilirubin decreased the SBP by 0.13 mm Hg. There 
is considerable physiological evidence showing increases in 
bilirubin affects renal hemodynamics and thus can decrease 
BP. For example, increases in bilirubin protect against exces-
sive tubuloglomerular feedback–mediated afferent arteriole 
vasoconstriction and can attenuate constriction to high levels 
of vasoconstrictors, such as Ang II.28 Moreover, bilirubin is 
one of the most potent antioxidants in the body,29 and Ang 
II–mediated superoxide production is significantly attenuated 
in aortic ring segments from moderately hyperbilirubinemic 
mice.21 The reduction of superoxide production in the vascula-
ture by bilirubin is associated with the increase in the bioavail-
ability of nitric oxide as reflected in the nitrate/nitrite levels in 
the plasma of chronically infused Ang II hypertensive mice 
made moderately hyperbilirubinemic.21
Our finding of a negative relationship between ALT and 
mortality is independent of all other concomitant liver tests. 
Previous studies, including a large systematic review, have 
shown variable associations.12,13,15,30–32 The reason for the 
increased risk seen with lower ALT is not clear. A recent 
study in the elderly (>70 years) showed that the increased 
risk associated with low ALT disappeared after adjustment 
for frailty,33 indicating that ALT may be a marker of aging and 
frailty. ALT levels are known to reduce with increasing age, 
suggesting that ALT may be a marker of functioning hepato-
cyte (and muscle mass) because ALT is primarily produced 
by the liver (with a small proportion from skeletal muscle). If 
this is true, then we speculate that the observed greater reduc-
tion in BP in this cohort with higher ALT levels may indicate 
better antihypertensive efficacy because the commonly used 
antihypertensive drugs, ACEI and ARBs, are prodrugs which 
require hepatic activation. Despite strong correlation between 
AST and ALT,34 the pattern of risk is U-shaped with AST in 
contrast to ALT. However, we are limited by our data to dis-
sect this further.
Both ALP and GGT are associated with increased mor-
tality risk, which is significant only at the higher end of the 
distribution. The novel finding in our study is the consistent 
association of both GGT and ALP with higher longitudinal 
BP. The magnitude of BP increase is higher with ALP than 
GGT, and this increase is over and above the 4 mm Hg annual 
decline in SBP seen in this cohort, which is related to anti-
hypertensive treatment. GGT has pro-oxidant effects because 
of its role in the extracellular catabolism of glutathione,35 and 
high GGT has been associated with incident diabetes mel-
litus36 metabolic syndrome and fatty liver.37 Recent prospec-
tive studies and a systematic review show that high GGT is 
positively associated with increased mortality or incidence of 
CVD,11,15,17–19 and our results reflect this. However, we do not 
see a clear association between GGT and cardiovascular mor-
tality once the effects of other liver tests are accounted for in 
the model. There is a linear increase of bilirubin with GGT 
levels, and the 24% excess risk of cardiovascular mortality 
associated with the highest quartile of GGT disappears once 
bilirubin is included in the model. The pro-oxidant and antiox-
idant properties, respectively,of GGT and bilirubin associated 
with opposite effects on cardiovascular risk when considered 
jointly indicates that GGT does not have a major independent 
impact on cardiovascular mortality. This is also supported by 
the lack of any incremental predictive utility when GGT is 
added to conventional clinical risk factors.
The effect of bilirubin and ALT on longitudinal SBP seems 
to be more prominent in the older age, in the overweight, 
and in those who consume alcohol, whereas both ALP and 
GGT show consistent effect on BP change in all subgroups 
in the opposite direction. It is possible that the variation in 
SBP seen with ALT and bilirubin may be because of altera-
tion in pharmacokinetic or pharmacodynamic parameters that 
are reflected in ALT and bilirubin levels. The results for DBP 
indicate that both ALT and bilirubin have no effect, whereas 
there is a clear positive effect of ALP and GGT. There are 2 
explanations for these findings: (1) the annual reduction in 
DBP is much lower than the annual reduction in SBP, so we 
may not be powered to find any additional BP lowering effect 
of bilirubin or ALT; (2) bilrubin and ALT do not have a truly 
causal effect on DBP change, and their effects on outcomes 
are unrelated to their effect on BP. Nevertheless, these are 
interesting findings showing the heterogeneity in liver bio-
chemistry effects on BP and require validation in independent 
controlled studies.
The strengths of the current study include a large cohort of 
nearly 12 000 hypertensive adults, 35 years of follow-up, high 
event rates, inclusion of the entire circulating range of liver 
enzymes (except levels suggestive of significant hepatocyte 
damage or obstructive liver disease). The generalizability of 
our findings is limited to middle-aged hypertensive patients 
of European ancestry. We acknowledge the exclusion of indi-
viduals without liver enzymes assessed at baseline from our 
analysis. However, other baseline demographic characteris-
tics of the excluded population were not different from those 
included in the study (data not shown). The long period over 
which our cohort was recruited means there will be variation 
in laboratory methods and reference values over time. We 
incorporated a variable on year of first visit strata (epochs) 
to adjust for secular trends in mortality and biochemical pro-
files. We have used a nonconventional metric of alcohol use 
because the coding for alcohol use was not consistent over 
time—this precluded analyses of alcohol dose effect. One of 
the inherent limitation of the continuous NRI is that it captures 
minor shifts in probabilities of outcomes and may be challeng-
ing to interpret in terms of clinical utility.38
 Finally, most of the 
patients were on combination antihypertensive therapy, and 
the BP control reflects overall BP reduction in a tertiary care 
clinic and does not inform on the effect of specific antihyper-
tensive drug class.
In conclusion, we confirm independent effects on mortality 
for liver enzymes and bilirubin within a range of 4 standard 
deviations from the mean in treated hypertensive patients. 
This merits further studies to elucidate the mechanisms under-
lying these results and explore the utility of these inexpensive 
markers for risk stratification and predicting antihypertensive 
treatment response.
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Perspectives
The study confirms that serum bilirubin and ALT are nega-
tively associated, whereas ALP and GGT are positively associ-
ated with mortality in treated hypertensive patients. Moreover, 
we show that higher serum ALP and GGT show consistently 
higher follow-up SBP. The implications for long-term BP 
control in outpatient clinical practice where these routinely 
performed inexpensive tests include stratifying hypertensive 
patients for more intensive follow-up or treatment escalation. 
Our findings warrant further studies to elucidate their under-
pinning mechanisms. We also show that in treated hyper-
tensive patients, the predictive potential for cardiovascular 
mortality with bilirubin and liver enzymes over conventional 
risk factors may be limited.
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What Is New?
•	The study shows that in treated hypertensive patients, serum bilirubin 
and alanine transaminase are negatively associated, whereas alkaline 
phosphatase and γ-glutamyltranspeptidase are positively associated 
with mortality, and aspartate transaminase show a U-shaped relation-
sip. Higher serum bilirubin and alanine transaminase are associated with 
lower follow-up blood pressure in contrast to alkaline phosphatase and 
γ-glutamyltranspeptidase.
What Is Relevant?
•	Baseline bilirubin and liver enzymes show independent effects on mor-
tality for liver enzymes and bilirubin within a range of 4 standard devia-
tions from the mean in treated hypertensive patients. Higher baseline 
alkaline phosphatase and γ-glutamyltranspeptidase show a positive 
association with higher follow-up blood pressure predicting poor blood 
pressure control.
Summary
This study confirms the previously described differential associa-
tion of various liver biochemistry variables on outcomes in treated 
hypertensive patients and additionally demonstrates a similar as-
sociation with longitudinal blood pressure. The predictive utility of 
liver enzymes and bilirubin over and above conventional Framing-
ham risk factors is limited,+ and thus, there is little support for us-
ing liver enzymes and bilirubin in any risk stratification strategies.
Novelty and Significance
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The Glasgow blood pressure clinic  
The Glasgow blood pressure clinic (GBPC) provides a secondary and tertiary level service to 
individuals with hypertension from the West of Scotland. Data from patients attending the clinic are 
stored in a computerised computerized database, which contains information on individuals 
attending the clinic from the mid 1970s until 2011. All patients are treated at GBPC until they 
achieve target BP and are maintained at that level for at least 3 months.  Currently the database has 
information on >16,000 hypertensive patients.  The West of Scotland research ethics service 
(WoSRES) of the National Health Service approved the study of the GBPC database (11/WS/0083).   
Clinical measurements  
Blood pressure measurements were taken manually 3 times, using standardized 
sphygmomanometers at each visit by specialist hypertension nurses; the mean of the last 2 
measurements was recorded at each visit. Patients attending the clinic were advised to take their 
regular medications as usual. Height and weight of all patients were measured using standardized 
equipment during each visit. Blood samples were collected at baseline and at regular intervals for 
estimation of routine hematological and biochemical indices, including liver function and renal 
function tests. All biochemical investigations were performed, at the Western Infirmary clinical 
laboratory service, on blood samples obtained at the first visit as part of routine screening. While 
the liver biochemistry were performed over a long-time scale, the assays were performed in the 
certified hospital laboratories on automated analyzers with robust attention to external quality 
control schemes (NEQAS [National External Quality Assessment Service]). Estimated glomerular 
filtration rate (eGFR) was calculated from baseline serum creatinine values using the Modification 
of Diet in Renal Disease Study Group (MDRD) equation.
1
 A structured format was used to measure 
tobacco (any versus none) and alcohol use (quantity and frequency of consumption). All data were 
electronically captured and maintained as a large single database.  
Outcome assessment  
Records kept by the General Register Office for Scotland ensured notification of a subject’s death 
(provided that it occurred in the United Kingdom) together with the primary cause of death 
according to the International Classification of Diseases, 10th Revision, Version for 2007 (ICD-10), 
codes. We considered cardiovascular deaths (CVD mortality; ICD-10 codes I00-I99), ischemic 
heart disease deaths (IHD mortality; ICD-10 codes 120-I25), and stroke deaths (stroke mortality; 
ICD-10 codes I60-I69) in the analysis. Deaths coded out with the aforementioned codes are 
classified as non-CVD deaths. Mortality data were collected up to April 2011, allowing a maximum 
of 35 years for participants who had been under follow up for the longest time. 
NRI and IDI 
 
The NRI value indicates the percentage improvement in correctly re-classifying the outcome 
(mortality) after incorporation of the new variable in the model. NRI is interpreted as the proportion 
of patients reclassified to a more appropriate risk category. cNRI counts the direction of change for 
every individual rather than the crossing of a threshold. Each patient is counted as either +1 or −1 
depending on whether the change in calculated risk was in the correct direction (higher for those 










 (1)  Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to 
estimate glomerular filtration rate from serum creatinine: a new prediction equation. 




Table S1A: Baseline characteristics of the study population, stratified by ALT quartile 
Variables  
ALT<=16 U/L  
(n=2168) 
ALT 17-24 U/L  
(n=3034) 
ALT 25-34 U/L  
(n=2184) 
ALT>=35 U/L  
(n=2331) 
p value  
Age yrs, mean (SD) 53.24 (16.38) 52.80 (14.45) 50.83 (12.50) 47.89 (12.11) <0.001 
Men, n(%) 578 (26.7) 1212 (40.0) 1232 (56.4) 1618 (69.4) <0.001 
BMI kg/m2, mean (SD) 26.21 (5.44) 27.41 (6.09) 28.25 (5.48) 29.22 (5.57) <0.001 
Smoking, n(%) 950 (45.1) 1316 (44.0) 962 (44.7) 1022 (44.9) 0.881 
Alcohol >6 units, n(%) 1064 (51.9) 1582 (54.6) 1325 (63.7) 1591 (71.8) <0.001 
SBP mmHg, mean (SD) 167.45 (29.72) 166.60 (28.68) 164.20 (27.77) 161.08 (25.93) <0.001 
DBP mmHGg, mean (SD) 96.07 (15.29) 96.73 (14.92) 98.19 (23.23) 98.36 (13.94) <0.001 
TC mmol/l, mean (SD) 5.84 (1.33) 5.92 (1.27) 6.01 (1.92) 6.08 (1.51) 0.011 
eGFR<60, n(%) 667 (31.0) 834 (27.7) 444 (20.5) 355 (15.4)  <0.001 
ALP U/L, median(IQR) 113 (71-174) 123 (78-182) 122 (78-180) 121 (78-184) <0.001 
AST U/L, median(IQR) 18 (16-22) 21 (18-25) 25 (21-29) 31 (26-40) <0.001 
GGT U/L, median(IQR) 18 (13-26) 23 (16-35) 31 (21-48) 46 (28-80) <0.001 
Bilirubin µmol/l, median (IQR) 9 (7-11) 9 (7-12) 10 (8-13) 11 (8-14) <0.001 
Albumin g/L, mean (SD) 42.81 (3.66) 43.40 (3.95) 44.10 (3.51) 44.61 (3.64) <0.001 
SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, eGFR=estimated 









AST 19-22 U/L  
(n=2582) 
ALT 23-28 U/L  
(n=2945) 
AST>=29 U/L  
(n=2738) 
p value  
Age yrs, mean (SD) 49.99 (14.98) 52.41 (15.07) 52.11 (14.16) 49.69 (13.25) <0.001 
Men, n(%) 916 (32.8) 1084 (42.0) 1535 (52.1) 1715 (62.3) <0.001 
BMI kg/m2, mean (SD) 27.39 (6.07) 27.38 (5.54) 27.87 (5.54) 28.49 (5.79) <0.001 
Smoking, n(%) 1277 (46.5) 1152 (45.4) 1250 (43.5) 1188 (44.3) 0.105 
Alcohol >6 units, n(%) 1458 (54.8) 1351 (55.1) 1609 (58.0) 1769 (68.5) <0.001 
SBP mmHg, mean (SD) 165.28 (29.68) 164.29 (28.18) 164.03 (27.47) 163.07 (27.60) 0.406 
DBP mmHGg, mean (SD) 96.97 (15.37) 96.03 (14.15) 96.86 (14.39) 98.57 (21.62) 0.112 
TC mmol/l, mean (SD) 5.87 (1.31) 5.90 (1.26) 5.91 (1.28) 6.06 (1.80) 0.325 
eGFR<60, n(%) 704 (25.5) 670 (26.2) 723 (24.8) 515 (19.0)  <0.001 
ALP U/L, median(IQR) 114 (71-173) 126 (79-180) 131 (82-187) 135 (83-193) <0.001 
ALT U/L, median(IQR) 16 (13-21) 20 (16-25) 26 (20-34) 40 (28-55) <0.001 
GGT U/L, median(IQR) 20 (14-30) 23 (16-35) 27 (18-42) 45 (26-79) <0.001 
Bilirubin µmol/l, median (IQR) 9 (6-11) 10 (7-12) 10 (8-13) 11 (8-14) <0.001 
Albumin g/L, mean (SD) 43.13 (3.84) 43.60 (3.40) 44.09 (3.67) 44.59 (3.65) <0.001 
SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, eGFR=estimated 











GGT 19-22 U/L  
(n=3040) 
ALT 23-28 U/L  
(n=2384) 
GGT>=29 U/L  
(n=1980) 
p value  
Age yrs, mean (SD) 48.75 (16.68) 52.51 (15.03) 52.42 (13.80) 51.07 (12.78) <0.001 
Men, n(%) 562 (23.6) 1266 (41.6) 1366 (57.3) 1273 (64.3) <0.001 
BMI kg/m2, mean (SD) 26.25 (5.32) 27.82 (5.84) 28.50 (5.93) 29.44 (6.09) <0.001 
Smoking, n(%) 830 (35.2) 1249 (41.8) 1138 (48.5) 997 (51.6) <0.001 
Alcohol >6 units, n(%) 1064 (46.8) 1468 (51.0) 1313 (58.3) 1258 (67.8) <0.001 
SBP mmHg, mean (SD) 159.94 (28.31) 162.31 (27.82) 162.72 (27.18) 161.94 (26.53) 0.164 
DBP mmHGg, mean (SD) 94.59 (14.37) 95.12 (19.23) 96.05 (13.58) 97.79 (23.69) <0.001 
TC mmol/l, mean (SD) 5.68 (1.25) 5.83 (1.26) 5.90 (1.50) 6.14 (1.28) <0.001 
eGFR<60, n(%) 565 (24.1) 777 (26.0) 545 (23.2) 382 (19.6)  <0.001 
ALP U/L, median(IQR) 108 (70-159) 133 (84-184) 141 (87-194) 146 (92-200) <0.001 
ALT U/L, median(IQR) 18 (14-23) 21 (16-28) 26 (19-35) 32 (23-46) <0.001 
AST U/L, median(IQR) 20 (17-24) 21 (18-26) 23 (19-28) 27 (21-34) <0.001 
Bilirubin µmol/l, median (IQR) 9 (7-12) 10 (7-13) 10 (8-13) 10 (8-13) <0.001 
Albumin g/L, mean (SD) 43.36 (3.86) 43.65 (3.65) 44.17 (3.48) 44.32 (3.62) <0.001 
SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, eGFR=estimated 










ALP 79-125 U/L 
(n=2957) 
ALP 126-183 U/L 
(n=2828) 
ALP>=184 U/L  
(n=1849) 
p value  
Age yrs, mean (SD) 48.31 (13.88) 50.67 (13.86) 51.14 (14.52) 52.94 (14.87) <0.001 
Men, n(%) 1302 (47.3) 1409 (47.7) 1378 (48.7) 925 (50.0) 0.266 
BMI kg/m2, mean (SD) 26.85 (5.20) 27.43 (5.59) 28.18 (5.68) 28.64 (6.36) <0.001 
Smoking, n(%) 1075 (40.3) 1310 (45.3) 1194 (42.8) 880 (48.1) <0.001 
Alcohol >6 units, n(%) 1801 (69.1) 1788 (63.3) 1449 (54.7) 935 (53.5) <0.001 
SBP mmHg, mean (SD) 164.66 (28.23) 165.93 (29.17) 160.33 (26.96) 163.70 (27.65) <0.001 
DBP mmHGg, mean (SD) 98.04 (15.40) 98.01 (14.72) 96.8 (20.88) 96.31 (14.11) <0.001 
TC mmol/l, mean (SD) 6.00 (1.50) 6.03 (1.31) 5.80 (1.21) 5.91 (1.99) 0.002 
eGFR<60, n(%) 565 (24.1) 777 (26.0) 545 (23.2) 382 (19.6)  <0.001 
ALT U/L, median(IQR) 22 (16-34) 24 (17-35) 23 (17-34) 24 (18-35) <0.001 
AST U/L, median(IQR) 22 (17-28) 23 (18-28) 23 (19-29) 24 (20-30) <0.001 
GGT U/L, median(IQR) 22 (14-36) 26 (17-43) 27 (18-46) 30 (20-49) <0.001 
Bilirubin µmol/l, median (IQR) 9 (7-12) 9 (7-12) 11 (8-14) 10 (8-13) <0.001 
Albumin g/L, mean (SD) 43.46 (4.05) 43.56 (3.76) 44.28 (3.39) 44.29 (3.59) <0.001 
SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, eGFR=estimated 










Bili 8-10 µmol/l 
(n=3348) 
Bili 10.1-13 µmol/l  
(n=2381) 
Bili>=13.1 µmol/l  
(n=2316) 
p value  
Age yrs, mean (SD) 50.88 (14.60) 51.70 (14.56) 51.37 (14.23) 50.10 (14.50) 0.587 
Men, n(%) 890 (31.3) 1448 (43.3) 1307 (54.9) 1502 (64.9) <0.001 
BMI kg/m2, mean (SD) 27.60 (6.21) 28.00 (5.78) 27.80 (5.42) 27.80 (5.67) <0.001 
Smoking, n(%) 1371 (49.3) 1497 (45.6) 970 (41.5) 906 (40.0) <0.001 
Alcohol >6 units, n(%) 1467 (54.5) 1773 (56.1) 1391 (62.1) 1425 (64.7) <0.001 
SBP mmHg, mean (SD) 166.23 (29.39) 163.81 (28.34) 163.36 (27.28) 162.17 (27.47) 0.002 
DBP mmHGg, mean (SD) 96.13 (15.42) 96.44 (14.38) 98.03 (22.46) 97.96 (13.87) <0.001 
TC mmol/l, mean (SD) 6.16 (1.88) 5.90 (1.26) 5.83 (1.16) 5.78 (1.45) <0.001 
eGFR<60, n(%) 737 (26.2) 796 (23.9) 524 (22.3) 459 (20.0)  <0.001 
ALP U/L, median(IQR) 100 (71-165) 133 (81-190) 142 (86-193) 141 (86-189) <0.001 
ALT U/L, median(IQR) 21 (15-30) 23 (17-33) 25 (18-36) 27 (19-40) <0.001 
AST U/L, median(IQR) 21 (17-26) 22 (18-28) 24 (20-30) 25 (20-32) <0.001 
GGT U/L, median(IQR) 24 (15-41) 26 (17-42) 28 (18-47) 31 (19-53) <0.001 
Albumin g/L, mean (SD) 42.98 (3.76) 43.78 (3.60) 44.22 (3.66) 44.53 (3.71) <0.001 
SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, eGFR=estimated 




Table S2: Liver biochemistry based group average effect on longitudinal changes in blood pressure 
Variables  SBP DBP 
 GEE β, 95% CI GEE β, 95% CI 
Log AST N=20053, G=3868 N=20053, G=3868 
 -1.59, -3.53; 0.32 0.60, -0.54; 1.76 
Log ALT  
 
N=19367, G=3733 N=19366, G=3733 
-1.94, -3.46; -0.42* 0.74, -0.30; 1.78 
Log GGT N=18083, G=3497 N=18082, G=3497 
2.92, 1.85; 3.98
†
 2.45, 1.73; 3.16
†
 
Log ALP N=20328, G=3920 N=20327, G=3920 
8.96, 7.48; 10.45
†
 4.03, 3.06; 5.01
†
 
Log Bilirubin N=19583, G=3779 N=19582, G=3779 
-2.03, -3.78; -0.29* 0.15, -0.99; 1.29 
*p<0.05, 
†
p<0.001, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase, 
CI=confidence interval, REF=reference group, N=total number of observations, G=total number of individuals/groups and GEE β=generalised 
estimating equations β coefficient . All models are adjusted for age, gender, epochs, BMI=body mass index, tobacco smoking, alcohol use and eGFR 




Table S3: Cox-Proportional hazard model of liver enzymes and mortality events (adjusted for other liver enzymes) 










 HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
ALT  N=2203/8223 N=1251/8223 N=683/8223 N=307/8277 N=952/8233 
Quartile 1 1  1  1  1  1  
Quartile 2 0.78* 0.70-0.87 0.79* 0.68-0.91 0.84 0.68-1.03 0.75 0.56-1.00 0.77* 0.65-0.91 
Quartile 3 0.80* 0.71-0.90 0.74* 0.62-0.88 0.72* 0.57-0.91 0.75 0.53-1.05 0.89 0.74-1.08 
Quartile 4 0.84* 0.74-0.97 0.83* 0.70-0.98 0.77* 0.61-0.97 0.81 0.57-1.15 0.86 0.70-1.05 
AST  N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
Quartile 1 1   1   1   1   1   
Quartile 2 0.87* 0.76-0.99 0.89 0.74-1.07 1.05 0.83-1.34 0.75 0.50-1.11 0.84 0.70-1.02 
Quartile 3 0.77* 0.67-0.87 0.83* 0.69-0.99 0.78 0.61-1.01 0.83 0.57-1.22 0.70* 0.57-0.85 
Quartile 4 0.94 0.82-1.08 0.99 0.82-1.20 1 0.77-1.30 1.03 0.69-1.53 0.89 0.72-1.09 
GGT  N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
Quartile 1 1   1   1   1   1   
Quartile 2 0.97 0.85-1.11 0.92 0.76-1.10 0.87 0.68-1.12 0.96 0.66-1.44 1.04 0.86-1.27 
Quartile 3 1.02 0.88-1.18 0.97 0.80-1.19 0.85 0.64-1.11 1.22 0.81-1.86 1.08 0.87-1.34 
Quartile 4 1.18* 1.02-1.38 1.10 0.90-1.36 0.98 0.74-1.29 1.34 0.87-2.07 1.29* 1.03-1.62 
ALP  N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
Quartile 1 1   1   1   1   1   
Quartile 2 1.05 0.92-1.20 1.06 0.88-1.26 1.06 0.83-1.36 0.91 0.63-1.31 1.04 0.85-1.27 
Quartile 3 1.25* 1.07-1.46 1.20 0.97-1.49 1.38* 1.04-1.84 0.78 0.49-1.26 1.30* 1.04-1.63 
Quartile 4 1.61* 1.39-1.87 1.68* 1.37-2.05 1.90* 1.45-2.49 1.35 0.89-2.07 1.54* 1.23-1.92 
Bilirubin  N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
Quartile 1 1  1  1  1  1  
Quartile 2 0.89 0.79-1.00 0.90 0.77-1.06 0.92 0.74-1.15 1.11 0.79-1.55 0.88 0.73-1.04 
Quartile 3 0.81* 0.70-0.94 0.77* 0.63-0.94 0.82 0.63-1.08 0.77 0.49-1.21 0.85 0.69-1.04 
Quartile 4 0.79* 0.68-0.92 0.80* 0.65-0.99 0.87 0.66-1.14 0.95 0.62-1.47 0.77* 0.61-0.96 
*p<0.05, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase 
(GGT)SBP=systolic blood pressure, DBP=diastolic blood pressure, CVD=Cardiovascular disease and IHD=ischemic heart disease, Non-CVD=non-
cardiovascular disease, HR=hazard Ratio, CI=confidence interval. All models are adjusted for age, gender, BMI, tobacco smoking, alcohol use, year of 
first visit (epoch), baseline SBP and DBP, eGFR, and final achieved SBP, serum cholesterol, diabetes status and the remaining concomitant liver tests 
(AST was not included with ALT).  
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Table S4: Liver markers and all-cause mortality in sub-groups.   
Variables  Age≤55 Age>55 BMI≤25 BMI>25 Alcohol Users Alcohol non-users 
 HR , 95% CI HR, 95% CI HR, 95% CI HR, 95% CI HR, 95% CI HR, 95% CI 
ALT  N=671/4222 N=902/2862 N=471/1834 N=1068/5133 N=579/2987 N=994/4097 
Q1 REF REF REF REF REF REF 
Q2 0.89, 0.70-1.11 0.69, 0.58-0.81
†




 0.81, 0.68-0.97* 




 0.78, 0.65-0.94* 0.75, 0.58-0.95* 0.75, 0.61-0.92* 
Q4 0.78, 0.60-1.01 0.64, 0.51-0.80
†
 0.65, 0.46-0.91* 0.68, 0.56-0.83
†
 0.70, 0.52-0.94* 0.69, 0.55-0.85
†
 
AST  N=696/4892 N=1041/3232 N=530/2111 N=1174/5879 N=683/3498 N=1054/4626 
Q1 1.17, 0.94-1.46 1.17, 0.99-1.37 1.33, 1.05-1.69* 1.09, 0.93-1.28 1.33, 1.09-1.63* 1.01, 0.85-1.20 
Q2 REF REF REF REF REF REF 
Q3 1.00, 0.80-1.26 0.82, 0.69-0.98* 1.04, 0.81-1.34 0.81, 0.69-0.96* 0.95, 0.76-1.17 0.84, 0.70-1.00* 
Q4 1.14, 0.91-1.42 1.05, 0.87-1.27 1.22, 0.93-1.60 1.000, 0.84-1.18 1.08, 0.85-1.38 1.04, 0.87-1.24 
GGT  N=605/3993 N=862/2733 N=447/1767 N=988/4849 N=558/2906 N=909/3820 
Q1 REF REF REF REF REF REF 
Q2 0.93, 0.74-1.18 0.93, 0.78-1.12 1.08, 0.84-1.37 0.89, 0.74-1.06 0.93, 0.75-1.15 0.96, 0.79-1.17 
Q3 1.13, 0.88-1.44 0.91, 0.74-1.13 1.27, 0.96-1.67 0.92, 0.76-1.12 0.87, 0.68-1.13 1.09, 0.89-1.33 
Q4 1.10, 0.85-1.43 1.10, 0.86-1.39 1.54, 1.11-2.13* 1.02, 0.83-1.27 0.82, 0.60-1.13 1.30, 1.05-1.61* 
ALP N=618/3994 N=791/2539 N=412/1706 N=968/4720 N=482/2626 N=927/3907 
Q1 REF REF REF REF REF REF 
Q2 1.09, 0.89-1.33 1.04, 0.86-1.26 0.93, 0.73-1.20 1.15, 0.97-1.35 1.15, 0.90-1.48 1.04, 0.89-1.23 
Q3 1.24, 0.98-1.57 1.18, 0.94-1.48 0.99, 0.74-1.34 1.34, 1.10-1.64* 1.39, 1.05-1.84* 1.17, 0.95-1.43 
Q4 1.59, 1.22-2.06* 1.24, 0.97-1.58 0.99, 0.71-1.38 1.55, 1.25-1.95
†
 1.41, 1.03-1.95* 1.40, 1.09-1.69* 
Bilirubin N=679/4278 N=907/2879 N=473/1839 N=1079/5201 N=580/3003 N=1006/4154 
Q1 REF REF REF REF REF REF 
Q2 0.83, 0.68-1.01 0.95, 0.80-1.12 0.92, 0.73-1.16 0.87, 0.74-1.01 0.75, 0.61-0.93
†
 0.99, 0.84-1.16 
Q3 0.76, 0.61-0.96* 0.89, 0.73-1.08 0.85, 0.65-1.12 0.80, 0.67-0.96* 0.65, 0.50-0.84
†
 0.94, 0.78-1.13 
Q4 0.79, 0.63-0.99* 0.79, 0.64-0.99* 0.72, 0.54-0.96* 0.79, 0.65-0.96* 0.63, 0.48-0.83
†
 0.90, 0.75-1.10 
*p<0.05, 
†
p<0.001, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase 



















35 Year Follow-up 
Base 
0.824 
[0.809 - 0.839] 
       
Base + Bilirubin 
0.827 











Base + ALP + 
Bilirubin 
0.831 











Base + LFT 
0.83 











20 Year Follow-up 
Base 
0.833 
[0.817 - 0.85] 
       
Base + Bilirubin 
0.837 











Base + ALP + 
Bilirubin 
0.84 











Base + LFT 
0.839 











10 Year Follow-up 
Base 
0.827 
[0.804 - 0.85] 
       
Base + Bilirubin 
0.828 











Base + ALP + 
Bilirubin 
0.833 











Base + LFT 
0.835 











Baseline model includes age, sex, systolic blood pressure, diastolic blood pressure, smoking status, alcohol use, body mass index, Cholesterol, epochs 
and chronic kidney disease status. AUC=Area under the curve, NRI=Net reclassification index, P=p value, IDI=Integrated descrimination index,  
ALP=alkaline phosphatase, LFT=Liver function tests, and CI=Confidence interval. 
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Table S6: Full risk discrimination and reclassification analysis 
 
Risk model- FU=35 years AUC 





P  NRI(Continuous) 
[95% CI] 
P  IDI 
[95% CI] 
P 
 base   0.824 
[0.809 - 0.839] 
       
 base+Albumin   0.824 
[0.809 - 0.839] 
0  0.003 
[-0.01-0.016] 
0.646  -0.06 
[-0.143-0.023] 
0.157  2e-04 
[-0.002-0.003] 
0.849 
 base+ALT   0.824 
[0.808 - 0.839] 
0  0.004 
[-0.007-0.015] 
0.452  0.083 
[-7e-04-0.166] 
0.051  0.001 
[-3e-04-0.003] 
0.109 
 base+AST   0.824 
[0.809 - 0.839] 
0  0.004 
[-0.005-0.013] 
0.343  0.047 
[-0.037-0.130] 
0.272  7e-04 
[-5e-04-0.002] 
0.277 
base+ALP   0.827 
[0.811 - 0.842] 
0.003  -4e-04 
[-0.017-0.016] 
0.962  0.074 
[-0.009-0.157] 
0.081  0.008 
[0.004-0.012] 
<0.001 
 base+GGT   0.824 
[0.808 - 0.839] 
0  -0.004 
[-0.013-0.006] 
0.457  0.008 
[-0.075-0.092] 
0.844  -1e-04 
[-9e-04-6e-04] 
0.755 
 base+Bilirubin   0.827 
[0.812 - 0.842] 
0.003  0.011 
[-0.004-0.027] 
0.136  0.165 
[0.082-0.249] 
<0.001  0.006 
[0.003-0.010] 
0.001 
 base+GGT+Bilirubin   0.827 
[0.812 - 0.842] 
0.003  0.002 
[-0.014-0.019] 
0.766  0.143 
[0.059-0.226] 
<0.001  0.006 
[0.002-0.010] 
0.003 
 base+Albumin+Bilirubin   0.827 
[0.812 - 0.842] 
0.003  0.010 
[-0.005-0.027] 
0.192  0.119 
[0.036-0.202] 
0.0051  0.006 
[0.002-0.01] 
0.004 
base+ALP+Bilirubin   0.831 
[0.816 - 0.846] 
0.007  0.029 
[0.008-0.050] 
0.007  0.299 
[0.215-0.382] 
<0.001  0.015 
[0.009-0.021] 
<0.001 
 base+ALT+Bilirubin   0.827 
[0.812 - 0.842] 
0.003  0.010 
[-0.007-0.026] 
0.249  0.172 
[0.089-0.255] 
<0.001  0.007 
[0.003-0.011] 
<0.001 
 base+AST+Bilirubin   0.827 
[0.812 - 0.842] 
0.003  0.011 
[-0.005-0.026] 
0.170  0.170 
[0.086-0.253] 
0<0.001  0.006 
[0.003-0.010] 
<0.001 
base+GGT+Albumin   0.823 
[0.808 - 0.839] 
-0.001  0.007 
[-0.007-0.020] 
0.324  -0.015 
[-0.098-0.068] 
0.723  1e-04 
[-0.003-0.003] 
0.927 
base+ALP+Albumin   0.827 
[0.812 - 0.842] 
0.003  6e-04 
[-0.019-0.020] 
0.949  0.159 
[0.075-0.242] 
<0.001  0.008 
[0.004-0.013] 
<0.001 
base+ALT+Albumin   0.824 
[0.809 - 0.839] 
0  0.011 
[-0.003-0.024] 
0.126  0.034 
[-0.050-0.117] 
0.430  0.001 
[-0.001-0.004] 
0.287 
base+AST+Albumin   0.824 0  0.003 0.667  0.027 0.531  8e-04 0.530 
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[0.808 - 0.839] [-0.011-0.017] [-0.057-0.110] [-0.002-0.003] 
base+GGT+ALT   0.823 
[0.808 - 0.839] 
-0.001  -8e-04 
[-0.013-0.011] 
0.887  0.095 
[0.012-0.178] 
0.025  0.002 
[-7e-04-0.004] 
0.189 
base+ALP+ALT   0.827 
[0.811 - 0.842] 
0.003  0.015 
[-0.002-0.032] 
0.086  0.107 
[0.024-0.191] 
0.011  0.009 
[0.005-0.014] 
<0.001 
35  base+ALP+GGT   0.827 
[0.811 - 0.842] 
0.003  -4e-04 
[-0.017-0.016] 
0.963  0.071 
[-0.012-0.154] 
0.095  0.008 
[0.004-0.012] 
<0.001 
35  base+AST+GGT   0.823 
[0.808 - 0.839] 
-0.001  0.002 
[-0.007-0.011] 
0.614  0.014 
[-0.069-0.098] 
0.735  6e-04 
[-0.001-0.002] 
0.467 
35  base+AST+ALP   0.826 
[0.811 - 0.842] 
0.002  0.011 
[-0.007-0.028] 
0.236  0.111 
[0.028-0.195] 
0.009  0.009 
[0.004-0.013] 
<0.001 
35  base+LFT   0.83 
[0.815 - 0.845] 
0.006  0.021 
[-0.001-0.042] 
0.064  0.291 
[0.208-0.374] 
<0.001  0.016 
[0.010-0.023] 
<0.001 
         
Risk model- FU=20 years AUC 
[95% CI]for the 
model 2  
  NRI(Categorical) 
[95% CI] 
P  NRI(Continuous) 
[95% CI] 
P  IDI 
[95% CI] 
P 
 base   0.833 
[0.817 - 0.85] 
       
 base+Albumin   0.833 
[0.817 - 0.849] 
0  -0.002 
[-0.021-0.017] 
0.841  -0.040 
[-0.131-0.051] 
0.386  9e-04 
[-0.002-0.003] 
0.479 
 base+ALT   0.833 
[0.816 - 0.849] 
0  -0.008 
[-0.022-0.007] 
0.303  0.041 
[-0.049-0.132] 
0.374  0.001 
[1e-04-0.003] 
0.028 
 base+AST   0.833 
[0.817 - 0.849] 
0  -0.011 
[-0.023-0.001] 
0.075  0.004 
[-0.087-0.095] 
0.934  5e-04 
[-1e-04-0.001] 
0.124 
 base+ALP   0.836 
[0.82 - 0.852] 
0.003  -0.002 
[-0.025-0.020] 
0.836  0.102 
[0.011-0.193] 
0.028  0.005 
[0.002-0.008] 
0.005 
 base+GGT   0.833 
[0.817 - 0.85] 
0  0.003 
[-0.013-0.019] 
0.676  0.066 
[-0.025-0.157] 
0.156  -1e-04 
[-0.0011-8e-04] 
0.767 
 base+Bilirubin   0.837 
[0.821 - 0.853] 
0.004  0.015 
[-0.010-0.040] 
0.255  0.176 
[0.085-0.267] 
<0.001  0.005 
[0.001-0.009] 
0.009 
 base+GGT+Bilirubin   0.837 
[0.821 - 0.853] 
0.004  0.015 
[-0.010-0.042] 
0.249  0.149 
[0.058-0.240] 
0.001  0.005 
[9e-04-0.009] 
0.016 
 base+Albumin+Bilirubin   0.837 
[0.82 - 0.853] 
0.004  0.008 
[-0.017-0.034] 
0.526  0.110 
[0.019-0.200] 





 base+ALP+Bilirubin   0.84 
[0.824 - 0.856] 
0.007  0.020 
[-0.009-0.050] 
0.177  0.304 
[0.213-0.395] 
<0.001  0.011 
[0.006-0.017] 
<0.001 
 base+ALT+Bilirubin   0.837 
[0.821 - 0.853] 
0.004  0.011 
[-0.014-0.037] 
0.388  0.140 
[0.049-0.231] 
0.003  0.006 
[0.002-0.010] 
0.002 
 base+AST+Bilirubin   0.837 
[0.821 - 0.853] 
0.004  0.013 
[-0.012-0.038] 
0.306  0.156 
[0.065-0.247] 
<0.001  0.005 
[0.001-0.009] 
0.007 
 base+GGT+Albumin   0.833 
[0.817 - 0.849] 
0  0.011 
[-0.010-0.032] 
0.314  0.018 
[-0.073-0.109] 
0.702  9e-04 
[-0.002-0.004] 
0.550 
 base+ALP+Albumin   0.836 
[0.82 - 0.852] 
0.003  0.005 
[-0.021-0.031] 
0.707  0.198 
[0.107-0.289] 
<0.001  0.006 
[0.002-0.010] 
0.005 
 base+ALT+Albumin   0.833 
[0.816 - 0.849] 
0  0.003 
[-0.018-0.024] 
0.771  0.018 
[-0.074-0.109] 
0.706  0.002 
[-6e-04-0.005] 
0.120 
 base+AST+Albumin   0.833 
[0.817 - 0.849] 
0  0.002 
[-0.018-0.022] 
0.847  -0.018 
[-0.109-0.073] 
0.698  0.001 
[-0.001-0.004] 
0.297 
 base+GGT+ALT   0.833 
[0.816 - 0.849] 
0  -0.008 
[-0.026-0.010] 
0.393  0.097 
[0.006-0.188] 
0.036  0.002 
[-2e-04-0.004] 
0.078 
 base+ALP+ALT   0.835 
[0.819 - 0.851] 
0.002  -0.014 
[-0.037-0.009] 
0.221  0.129 
[0.038-0.22] 
0.005  0.007 
[0.003-0.010] 
<0.001 
 base+ALP+GGT   0.836 
[0.82 - 0.852] 
0.003  0.002 
[-0.021-0.026] 
0.848  0.107 
[0.016-0.198] 
0.020  0.005 
[0.001-0.008] 
0.007 
 base+AST+GGT   0.833 
[0.817 - 0.849] 
0  -0.010 
[-0.027-0.008] 
0.266  0.033 
[-0.058-0.124] 
0.476  6e-04 
[-8e-04-0.002] 
0.407 
 base+AST+ALP   0.835 
[0.819 - 0.852] 
0.002  -0.009 
[-0.031-0.014] 
0.435  0.157 
[0.066-0.248] 
<0.001  0.006 
[0.002-0.009] 
0.001 
 base+LFT   0.839 
[0.823 - 0.855] 
0.006  0.006 
[-0.025-0.037] 
0.720  0.282 
[0.191-0.373] 
<0.001  0.013 
[0.007-0.019] 
<0.001 
         
Risk model- FU=10 years AUC 
[95% CI]for the 
model 2  
  NRI(Categorical) 
[95% CI] 
P  NRI(Continuous) 
[95% CI] 
P  IDI 
[95% CI] 
P 
 base   0.827 
[0.804 - 0.85] 
       
 base+Albumin   0.828 
[0.805 - 0.851] 
0.001  -0.018 
[-0.055-0.019] 
0.348  0.129 
[0.003-0.254] 
0.044  0.003 
[-8e-04-0.007] 
0.117 
 base+ALT   0.827 0  0.012 0.273  0.060 0.347  0.002 0.024 
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[0.803 - 0.85] [-0.010-0.034] [-0.065-0.186] [2e-04-0.003] 
 base+AST   0.827 
[0.803 - 0.85] 
0  0.019 
[-0.013-0.051] 
0.250  0.085 
[-0.041-0.210] 
0.186  0.003 
[8e-04-0.005] 
0.007 
 base+ALP   0.832 
[0.809 - 0.855] 
0.005  0.009 
[-0.028-0.045] 
0.645  0.184 
[0.058-0.309] 
0.004  0.004 
[-2e-04-0.008] 
0.066 
 base+GGT   0.828 
[0.804 - 0.851] 
0.001  0.005 
[-0.014-0.024] 
0.596  0.085 
[-0.040-0.211] 
0.184  1e-04 
[-0.001-0.002] 
0.890 
 base+Bilirubin   0.828 
[0.804 - 0.851] 
0.001  -0.014 
[-0.056-0.028] 
0.508  0.050 
[-0.076-0.175] 
0.437  0.005 
[0.001-0.009] 
0.013 
 base+GGT+Bilirubin   0.828 
[0.805 - 0.851] 
0.001  -0.009 
[-0.051-0.033] 
0.668  0.087 
[-0.038-0.213] 
0.172  0.005 
[8e-04-0.010] 
0.021 
 base+Albumin+Bilirubin   0.829 
[0.805 - 0.852] 
0.002  -0.007 
[-0.051-0.037] 
0.745  0.126 
[5e-04-0.252] 
0.049  0.007 
[0.002-0.013] 
0.006 
 base+ALP+Bilirubin   0.833 
[0.811 - 0.856] 
0.006  0.0102 
[-0.035-0.055] 
0.660  0.219 
[0.093-0.344] 
<0.001  0.009 
[0.003-0.015] 
0.002 
 base+ALT+Bilirubin   0.828 
[0.804 - 0.851] 
0.001  -0.023 
[-0.061-0.014] 
0.219  0.027 
[-0.099-0.152] 
0.674  0.006 
[0.002-0.010] 
0.003 
 base+AST+Bilirubin   0.827 
[0.804 - 0.851] 
0  0.003 
[-0.039-0.044] 
0.899  0.121 
[-0.005-0.246] 
0.059  0.007 
[0.003-0.011] 
<0.001 
 base+GGT+Albumin   0.828 
[0.806 - 0.851] 
0.001  0.009 
[-0.032-0.050] 
0.663  0.162 
[0.037-0.287] 
0.011  0.004 
[-7e-04-0.008] 
0.099 
 base+ALP+Albumin   0.834 
[0.812 - 0.857] 
0.007  -0.007 
[-0.048-0.034] 
0.744  0.309 
[0.184-0.435] 
<0.001  0.007 
[0.002-0.013] 
0.013 
 base+ALT+Albumin   0.828 
[0.805 - 0.851] 
0.001  -0.018 
[-0.0566-0.021] 
0.368  0.115 
[-0.010-0.240] 
0.073  0.004 
[3e-04-0.009] 
0.037 
 base+AST+Albumin   0.828 
[0.805 - 0.851] 
0.001  -0.007 
[-0.049-0.036] 
0.754  0.108 
[-0.017-0.234] 
0.091  0.006 
[0.001-0.010] 
0.010 
 base+GGT+ALT   0.828 
[0.804 - 0.851] 
0.001  -0.007 
[-0.036-0.022] 
0.648  0.154 
[0.029-0.280] 
0.017  0.003 
[2e-04-0.005] 
0.034 
 base+ALP+ALT   0.832 
[0.809 - 0.855] 
0.005  0.008 
[-0.032-0.048] 
0.691  0.207 
[0.082-0.333] 
0.001  0.005 
[0.001-0.010] 
0.012 
 base+ALP+GGT   0.832 
[0.809 - 0.855] 
0.005  -7e-04 
[-0.037-0.036] 
0.969  0.211 
[0.085-0.336] 
0.001  0.004 
[-4e-04-0.008] 
0.080 
 base+AST+GGT   0.827 
[0.804 - 0.851] 
0  0.001 
[-0.037-0.040] 
0.942  0.074 
[-0.052-0.199] 





 base+AST+ALP   0.832 
[0.809 - 0.855] 
0.005  0.007 
[-0.037-0.051] 
0.762  0.241 
[0.116-0.367] 
<0.001  0.007 
[0.002-0.011] 
0.003 
 base+LFT   0.835 
[0.813 - 0.857] 
0.008  -0.004 
[-0.057-0.048] 
0.873  0.353 
[0.228-0.479] 





Baseline model includes age, sex, systolic blood pressure, diastolic blood pressure, smoking status, alcohol use, body mass index, Cholesterol, epochs and 
chronic kidney disease status. ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase 
(GGT), AUC=area under the ROC curve, FU=follow-up in years, CI=confidence interval,  P=p value, NRI=net reclassification index, IDI=integrated 
discrimination index.   
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*Numbers included in the cubic regression spline models.  
 
ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-
glutamyltransferase (GGT)
Excluded (n=408): 
ALT>100 U/L  
N=12000 
Glasgow Blood Pressure Clinic (GPBC) 
Database: N=16011 
Excluded (n=4011): Missing data on any of the 



















































Supplementary Figure S2: Bivariate correlations between liver enzymes and bilirubin 
 




Supplementary Figure S3: Liver biochemistry and longitudinal change in SBP. The rate of change in systolic 
blood pressure with liver parameters and their 95% confidence limits are presented. The results are stratified 
by potential confounding factors. 
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Supplementary Figure S4: Cox proportional hazard model for markers of liver dysfunction and all-cause 
mortality before and after imputation of missing data. It is a forest plot representing the point estimates of 
hazard ratios and their 95% confidence intervals. 
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